Yahoo Finance Target Dives On Weak Earnings, Guidance With Consumers 'Pressured'; TJX Surges; BJ's Reports
Target dived after the discount giant missed on earnings and guided lower, citing "pressured" consumers. TJX earnings beat.
Target dived after the discount giant missed on earnings and guided lower, citing "pressured" consumers. TJX earnings beat.
Trump legal team argues Attorney General Merrick Garland did not have the legal authority to appoint Jack Smith as special counsel
Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meeting of 20 June 2024, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the listing on Euron
Sales of previously owned homes declined for the third straight month in May as prices hit an all-time high. Year-over-year sales were down 2.8%.
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“Gamida Cell”), brings over two decades of extensive experience in leading clinical and drug dev
Senior politicians discuss the challenges of meeting climate change targets at the 41st summit.
Sherri Papini's kidnapping case propelled her and her family into the national spotlight
A police officer was among the victims of the shooting, which was reported at the Mad Butcher market in Fordyce, about 70 miles south of Little Rock
Chase Briscoe has been mentioned as the leading candidate for the No. 19 car in 2025.
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or commo
THOUSAND OAKS, Calif., June 21, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for "Best Product for Orphan/Rare Diseases." The award was presented to Pierre Fabre Laboratorie
Jennifer Hudson's mom, Darnell Donerson, and brother, Jason Hudson, were tragically murdered in 2008
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
With top growth stocks like Nvidia, Apple near record highs, keep in mind these proven rules for when to sell stocks.
While laying an AI foundation with Amazon Bedrock, Amazon stock lays the groundwork for a breakout to a record high.
Baltic Horizon Fund applies for a waiver of negative pledge undertaking in relation to Baltic Horizon Fund EUR 42 million 5-year floating rate bonds maturing in 2028 (ISIN EE3300003235, the Bonds). The current outstanding nominal amount of the Bonds is EUR 29,999,999.40 and according to the terms and conditions of the Bonds (the Terms and Conditions) Baltic Horizon Fund is to mandatorily redeem Bonds in outstanding nominal amount of EUR 7,999,999.40 by 8 July 2024. In the light of the mandatory
OSAKA, Japan & CAMBRIDGE, Mass., June 21, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to tr
21st June 2024 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares'' or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, announces that following our previous RNS on 13th June 2024, the Group has decided to fully impair its investment in FlowBank Holdings SA, effective immediately. This has resulted in an impairment charge of £21,813,042. As previously announced, the Group’s exposure to FlowBank SA as
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) has receive
The Global Deep Brain Stimulation Devices Market Size was Valued at USD 1.30 Billion in 2023 and the Worldwide Deep Brain Stimulation Devices Market Size is Expected to Reach USD 3.44 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Abbott, Medtronic, Neuropace Inc., Renishaw Plc., Beijing Pinchi Medical Equipment Co. Ltd, Boston Scientific Corporation, Nexstim, LivaNova Plc, Aleva Neurotherapeutics S.A., and Others Key Vendors.New
New OB 2nd/3rd Trimester Certificate Now Available, Completes Suite of Maternal Fetal Health Certification ProductsROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) -- Inteleos, a global non-profit healthcare certification organization, today announced that its Point-of-Care Ultrasound Certification Academy (PCA) launched its comprehensive Maternal Fetal Health Certification, with its new Obstetrics (OB) 2nd/3rd Trimester Clinical Certificate. This latest addition completes the PCA’s comprehensive